NUV-1511 Phase 1/2 Trial Begins with First Patient Dosing for Advanced Solid Tumors

Nuvation Bio Inc., a biopharmaceutical firm focused on developing innovative oncology treatments, has reached a significant milestone with the initiation of a Phase 1/2 clinical trial for its first drug-drug conjugate (DDC), NUV-1511. The company, known for its novel therapeutic candidates, is led by David Hung, M.D., who has a history of founding successful biopharma companies.

The NUV-1511 trial is designed with a flexible dosing regimen to explore two schedules and determine the optimal Phase 2 dosage. The primary focus of the study is on evaluating the safety, tolerability, and pharmacokinetics of the drug, as well as its clinical efficacy in patients with various types of advanced solid tumors. These patients have previously undergone treatment with Enhertu® and/or Trodelvy® and have shown progression post-treatment. The types of cancers targeted in the study include HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer, advanced pancreatic cancer, and platinum-resistant ovarian cancer.

Nuvation Bio's proprietary platform is built on the development of potent chimeric small molecules that selectively target cancer cells while minimizing effects on healthy tissues. The company's portfolio is diverse, with each candidate aimed at treating some of the most challenging cancers. Founded in 2018 by Dr. Hung, Nuvation Bio has quickly established a presence in the biopharmaceutical industry with offices in New York and San Francisco.

The company's mission is to address significant unmet needs in oncology, and the advancement of NUV-1511 into clinical trials represents a step forward in achieving this goal. With a robust pipeline of oncology therapeutics, Nuvation Bio is poised to contribute meaningfully to the field of cancer treatment.

It is important to note that the information provided in this summary is based on the company's current understanding and expectations. The actual outcomes may vary due to a range of factors, including regulatory challenges, patient enrollment issues, and unforeseen side effects. The company's filings with the SEC provide a more detailed analysis of the risks and uncertainties associated with its operations and clinical trials.